Athan Kuliopulos
Oasis Pharmaceuticals, LLC · Tufts Medical Center · Tufts Medical Center (Hemostasis and Thrombosis Laboratory)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Athan Kuliopulos as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:38 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05680233 · Safety Study of OA-235i in Subjects With Nonalcoholic SteatohepatitisOasis Pharmaceuticals, LLC · completed · Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver · study director
- Ph2NCT02561000 · Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary InterventionTufts Medical Center · completed · Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease · study director
- Ph1NCT01806077 · Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk FactorsTufts Medical Center · completed · Vascular Disease, Coronary Artery Disease Risk Factors Multiple · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke TherapyR42HL160429 · NHLBI · OASIS PHARMACEUTICALS · fiscal years 2023 to 2025 · $50,000 awarded in 2025Same name and institution; not confirmed by an ID
- Metabolic Reprogramming by Protease-activated Receptor 2R01DK128364 · NIDDK · TUFTS MEDICAL CENTER · fiscal years 2022 to 2024 · $567,618 awarded in 2024Same name and institution; not confirmed by an ID
- Development of liver homing PAR2 pepducins for the treatment of Hepatocellular CarcinomaR41CA272065 · NCI · OASIS PHARMACEUTICALS · fiscal years 2022 · $392,485 awarded in 2022Same name and institution; not confirmed by an ID
- Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke TherapyR41HL160429 · NHLBI · OASIS PHARMACEUTICALS · fiscal years 2021 · $361,774 awarded in 2021Same name and institution; not confirmed by an ID
- Matrix Metalloprotease-PAR1 Regulation of AtherosclerosisR01HL136485 · NHLBI · TUFTS MEDICAL CENTER · fiscal years 2018 to 2021 · $646,131 awarded in 2021Same name and institution; not confirmed by an ID
- PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary FibrosisR42HL140701 · NHLBI · OASIS PHARMACEUTICALS · fiscal years 2018 to 2020 · $740,572 awarded in 2020Same name and institution; not confirmed by an ID
- Development of PAR2 Pepducins as a Novel NASH TreatmentR44DK101240 · NIDDK · OASIS PHARMACEUTICALS · fiscal years 2017 to 2019 · $1,056,106 awarded in 2019Grant number is on one of their registry trials
- Development of PAR2 Pepducins for the Treatment of Atopic DermatitisR42AR067617 · NIAMS · OASIS PHARMACEUTICALS · fiscal years 2015 to 2017 · $750,000 awarded in 2017Same name and institution; not confirmed by an ID
- Development of PAR4 Pepducins as a Novel Antithrombotic TreatmentR41HL134517 · NHLBI · OASIS PHARMACEUTICALS · fiscal years 2017 · $366,484 awarded in 2017Same name and institution; not confirmed by an ID
- TRIP-PCI: PAR1 Pepducin-Based Interventions in Arterial ThrombosisP50HL110789 · NHLBI · TUFTS MEDICAL CENTER · fiscal years 2012 to 2016 · $1,794,671 awarded in 2016Grant number is on one of their registry trials
- Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitisR42DK101240 · NIDDK · OASIS PHARMACEUTICALS · fiscal years 2013 to 2015 · $871,014 awarded in 2015Same name and institution; not confirmed by an ID
- Thrombin Receptor-G Protein Signaling MechanismsR01HL064701 · NHLBI · TUFTS MEDICAL CENTER · fiscal years 2001 to 2011 · $402,500 awarded in 2011Same name and institution; not confirmed by an ID
- CTRIP: MMP1-PAR1-based Interventions in Arterial ThrombosisRC2HL101783 · NHLBI · TUFTS MEDICAL CENTER · fiscal years 2009 to 2010 · $601,043 awarded in 2010Same name and institution; not confirmed by an ID
- Inter-Cellular Signaling of Invastion Receptors in the Tumor MicroenvironmentR01CA122992 · NCI · TUFTS MEDICAL CENTER · fiscal years 2007 to 2010 · $305,900 awarded in 2010Same name and institution; not confirmed by an ID
- Protease-activated receptors in vascular integrity and dysfunctionR01HL057905 · NHLBI · TUFTS MEDICAL CENTER · fiscal years 1999 to 2010 · $402,500 awarded in 2010Same name and institution; not confirmed by an ID
- SIGNAL TRANSDUCTION OF A G PROTEIN COUPLED RECEPTORR29GM052926 · NIGMS · TUFTS MEDICAL CENTER · fiscal years 1995 to 1999 · $85,452 awarded in 1999Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:38 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease.Arterioscler Thromb Vasc Biol · 201681 citationsRCR 2.8
- PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study.Arterioscler Thromb Vasc Biol · 202031 citationsRCR 1.5
- 22 citationsRCR 0.4